EA201170921A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA201170921A1
EA201170921A1 EA201170921A EA201170921A EA201170921A1 EA 201170921 A1 EA201170921 A1 EA 201170921A1 EA 201170921 A EA201170921 A EA 201170921A EA 201170921 A EA201170921 A EA 201170921A EA 201170921 A1 EA201170921 A1 EA 201170921A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition
tromethamine
pyrazine
phenylalanine
Prior art date
Application number
EA201170921A
Other languages
English (en)
Inventor
Алок Б. Намдео
Н. Субраманиан
Субхас Баларам Бховмик
Original Assignee
Сан Фарма Адвансед Ресёрч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресёрч Компани Лимитед filed Critical Сан Фарма Адвансед Ресёрч Компани Лимитед
Publication of EA201170921A1 publication Critical patent/EA201170921A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к парентеральной фармацевтической композиции, включающей терапевтически эффективные количества N-(2-пиразин)карбонил-L-фенилаланин-L-лейцин бороновой кислоты, или ее солей, или ее производных и трометамин, где композиция является стабильной.
EA201170921A 2009-01-09 2010-01-08 Фармацевтическая композиция EA201170921A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN58MU2009 2009-01-09
PCT/IN2010/000015 WO2010089768A2 (en) 2009-01-09 2010-01-08 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
EA201170921A1 true EA201170921A1 (ru) 2012-01-30

Family

ID=42542466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170921A EA201170921A1 (ru) 2009-01-09 2010-01-08 Фармацевтическая композиция

Country Status (10)

Country Link
US (1) US9095514B2 (ru)
EP (1) EP2379077A4 (ru)
JP (1) JP5689816B2 (ru)
KR (1) KR20110114562A (ru)
CN (1) CN102292086B (ru)
AU (1) AU2010211981A1 (ru)
CA (1) CA2748921A1 (ru)
EA (1) EA201170921A1 (ru)
MX (1) MX2011007192A (ru)
WO (1) WO2010089768A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
WO2012047845A1 (en) 2010-10-05 2012-04-12 App Pharmaceuticals Bortezomib formulations stabilised with boric
WO2013128419A2 (en) * 2012-03-02 2013-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
CN103720666B (zh) * 2013-12-16 2015-11-25 亿腾药业（泰州）有限公司 一种注射用硼替佐米冻干制剂的制备方法
US20170143622A1 (en) * 2014-07-04 2017-05-25 Dr. Reddy's Laboratories Limited Stable liquid ready-to-use injectable formulation of bortezomib
EP3031811A1 (en) 2014-12-09 2016-06-15 Teva Pharmaceuticals Ltd. Malic acid esters of bortezomib
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
KR101807462B1 (ko) * 2017-03-09 2017-12-08 씨제이헬스케어 주식회사 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
JP7423028B2 (ja) * 2017-11-01 2024-01-29 日医工岐阜工場株式会社 ボルテゾミブを含有する凍結乾燥医薬組成物
WO2022094396A1 (en) 2020-11-02 2022-05-05 Spes Pharmaceuticals Inc. Aqueous compositions of bortezomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2359391T3 (es) * 2001-01-25 2011-05-23 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulación de compuestos de acido boronico.
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20080220416A1 (en) * 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
WO2006001965A2 (en) 2004-05-24 2006-01-05 Abgenix, Inc. Reducing the risk of human anti-human antibodies through v gene manipulation
MX2010002100A (es) * 2007-08-21 2010-03-26 Alza Corp Composiciones de liposomas para administracion in vivo de compuestos de acido boronico.

Also Published As

Publication number Publication date
WO2010089768A2 (en) 2010-08-12
MX2011007192A (es) 2011-10-04
US20110275597A1 (en) 2011-11-10
EP2379077A2 (en) 2011-10-26
JP2012514633A (ja) 2012-06-28
CN102292086B (zh) 2013-05-08
US9095514B2 (en) 2015-08-04
CN102292086A (zh) 2011-12-21
CA2748921A1 (en) 2010-08-12
EP2379077A4 (en) 2013-09-11
JP5689816B2 (ja) 2015-03-25
KR20110114562A (ko) 2011-10-19
WO2010089768A3 (en) 2010-11-04
AU2010211981A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
EA201170921A1 (ru) Фармацевтическая композиция
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
EA201270216A1 (ru) Фармацевтический состав
EA201071144A1 (ru) Гетероциклические производные
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201391822A1 (ru) Новые производные пиридина
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201290632A1 (ru) Производные бетулина
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591064A1 (ru) Новые производные пиридина
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201290416A1 (ru) Новые спиропиперидиновые соединения
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
EA201300388A1 (ru) Соединения замещенного бензамида
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA201591499A1 (ru) Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств